Showing 2 posts of 2 posts found.


AstraZeneca’s cediranib combo misses main goal in platinum-sensitive relapsed ovarian cancer

March 13, 2020
Medical Communications, Research and Development AstraZeneca, cediranib, lynparza, pharma, trial failure

Newly revealed Phase 3 data has shown that AstraZeneca’s oral vascular endothelial growth factor receptor (VEGFR) inhibitor cediranib, when combined …

AZ withdraws European filing for ovarian cancer therapy

September 22, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AstraZeneca, EMA, cediranib, ovarian cancer

AstraZeneca is no longer seeker European approval for its oral multi-VEGF receptor inhibitor cediranib for treatment of ovarian cancer after withdrawing …

Latest content